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Abstract
Background: Modulation of the immune system by genetically modified lymphoma cell vaccines
is of potential therapeutic value in the treatment of B cell lymphoma. However, the anti-tumor
effect of any single immunogene transfer has so far been limited. Combination treatment of
recombinant IL-2 and IL-12 has been reported to be synergistic for inducing anti-tumor responses
in solid tumors but the potential of IL-2/IL-12 gene modified B cell lymphoma cells has not been
explored yet.
Methods: Using three different human B cell lymphoma cell lines and primary samples from
patients with B cell neoplasms, expression levels of the coxsackie B-adenovirus receptor (CAR)
and alpha (v) integrins were analyzed by fluorescence-activated cell sorter (FACS). Adenoviral
transduction efficiencies were determined by GFP expression analysis and IL-2 and IL-12 cytokine
production was quantified by enzyme-linked immunosorbent (ELISA) assays. Proliferative activities
of peripheral blood mononuclear cells (PBMC) stimulated with either cytokine derived from
supernatants of transduced lymphoma cells were measured by cell proliferation (MTT) assays. An
EuTDA cytotoxicity assay was used to compare cytotoxic activities of IL-2 and/or IL-12 stimulated
PBMC against unmodified lymphoma cells.
Results: We found that B cell lymphoma cell lines could be transduced with much higher efficiency
than primary tumor samples, which appeared to correlate with the expression of CAR. Adenoviral-
expressed IL-2 and IL-12 similarly led to dose-dependent increases in proliferation rates of PBMC
obtained from healthy donors. IL-2 and/or IL-12 transduced lymphoma cells were co-cultured with
PBMC, which were assayed for their cytolytic activity against unmodified lymphoma cells. We found
that IL-2 stimulated PBMC elicited a significant anti-tumor effect but not the combined effect of IL-
2/IL-12 or IL-12 alone.
Conclusion: This study demonstrates that the generation of recombinant adenovirus modified
lymphoma cell vaccines based on lymphoma cell lines expressing IL-2 and IL-12 cytokine genes is
technically feasible, induces increases in proliferation rates and cytotoxic activity of co-cultured
PBMC, and warrants further development for the treatment of lymphoma patients in the future.
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Lymphoma cells are attractive targets for gene transfer,
because these cells are potentially susceptible to immuno-
therapeutic strategies [1]. Among the various cancer gene
therapies using a variety of genes with different gene trans-
fer systems, immunogene therapy focuses on the use of
genes for cytokines, chemokines, and co-stimulatory mol-
ecules [2]. Using an ex vivo approach of tumor cell trans-
duction, it was shown that many cytokines could
modulate tumorigenicity and protect the host from
untreated tumor cells [3]. However, the effect of any single
immunogene transfer has been limited, especially against
low immunogenic tumors [4].
Interleukin-2 (IL-2) and interleukin-12 (IL-12) are
cytokines that elicit strong antitumor effects by stimulat-
ing immune cells, including T cells and natural killer (NK)
cells. Although either cytokine stimulates the prolifera-
tion of T cells, the production of interferon-γ (IFN-γ) by
NK cells, and ultimately the cytolytic activity, the magni-
tude, and the spectrum of stimulatory effects by IL-2 and
IL-12 are different. Although IL-2 is a stronger stimulator
of proliferation and cytolytic activity, IL-12 is a stronger
inducer of IFN-γ from NK cells and activated T cells.
Although the combination of recombinant IL-2 and IL-12
treatment has been reported to be synergistic for inducing
anti-tumor responses, systemic administration of these
cytokines causes toxic side effects. Recent reports of intra-
tumoral co-injection of adenoviral vectors expressing IL-2
and IL-12 demonstrated the regression of pre-established
solid tumors with high frequency [5]. However, the signif-
icance of IL-2 and IL-12 immunogene therapy of hemat-
opoietic neoplasms such as B cell lymphoma, has not
been addressed yet.
Recently, we described an adenoviral protocol accom-
plishing highly efficient gene transfer to B-lymphoma cell
lines [6]. The use of genes or genetically modified cells for
therapeutic benefit may have a significant therapeutic role
for patients with B cell lymphomas in the future. Adoptive
immunotherapy using donor leukocyte infusion to treat
aggressive B cell neoplasms in immunosuppressed
patients has shown great promise clinically, and studies of
idiotypic vaccination in patients with low grade B cell
neoplasms are also underway. Results from in vitro and
animal studies continue to suggest that it may become
possible to use the immune system for therapeutic bene-
fit, and many current basic research strategies in the gene
therapy of B cell lymphoma are based on immune modu-
lation of T cells or tumor cells themselves. Other major
approaches to gene therapy for B cell malignancies are the
introduction of directly toxic or suicide genes into B cells.
In the present study, we have evaluated the relationship
between the amount of cytokine production by the com-
bination IL-2 and IL-12 and the in vitro effective anti-
tumor activity. Using three different human B cell lym-
phoma cell lines and primary samples from patients with
B cell neoplasms, we transduced both IL-2 and IL-12
genes by adenoviral vectors, and monitored cytokine pro-
duction and effects on proliferation and cytolytic activity
of co-cultured human peripheral blood mononuclear
cells (PBMC).
Methods
Cell culture and primary lymphoma cells
The following cell lines were analyzed: Raji (human
Burkitt lymphoma cell line; obtained from "Deutsche
Sammlung von Mikroorganismen und Zellkulturen"
(DSMZ), Braunschweig, Germany), Daudi (human
Burkitt lymphoma cell line; obtained from DSMZ), and
OCI-Ly8-LAM53 (human follicular lymphoma cell line;
obtained from R. Levy, Stanford University, CA). The cell
lines were grown in RPMI 1640 with Glutamax (Life Tech-
nologies, Berlin, Germany) supplemented with 10% heat-
inactivated fetal calf serum (FCS) (PAA, Martinsried, Ger-
many), 50 µg/ml streptomycin, and 50 µg/ml penicillin
(PAA), and were kept in a humified incubator with 5%
CO2 at 37°C. Virus propagation was performed in the Ad5
E1-transformed human embryonic retina cell line 911 [7].
This cell line was grown in Dulbecco's modified Eagle's
medium (DMEM) (Life Technologies) supplemented
with 10% FCS, 50 µg/ml streptomycin, and 50 µg/ml
penicillin.
Non-adherent Ficoll-Hypaque (Seromed, Berlin, Ger-
many) separated human PBMC were obtained from
whole blood from healthy donors and maintained in
RPMI 1640 with Glutamax (Life Technologies) supple-
mented with 10% FCS (PAA), 50 µg/ml streptomycin, and
50 µg/ml penicillin. Cytokine-induced killer (CIK) cells
were generated as described previously [8,9]. In brief, 100
U/ml recombinant interferon-gamma (Boehringer Man-
nheim, Germany) was added on day 0. After 24 h of incu-
bation, 50 ng/ml of an antibody against CD3, 100 U/ml
interleukin-1 (IL-1), and 300 U/ml interleukin-2 (IL-2)
(PromoCell, Heidelberg, Germany) were added. Cells
were incubated at 37°C in a humified atmosphere of 5%
CO2 and subcultured every 3 days in fresh complete
medium and IL-2.
Five patients diagnosed with lymphoma were included
into this study; four patients with chronic B cell lym-
phocytic leukemia (B-CLL) and one patient with immu-
nocytoma (IC). After informed consent, peripheral blood
was obtained and lymphoma cells were isolated by Ficoll-
Hypaque (Seromed) density centrifugation. Cell surface
antigens were analyzed for the expression of CD19,
integrin avβ3, integrin avβ5, and the coxsackie B-adenovi-
rus receptor (CAR). Primary cultures were maintained inPage 2 of 8
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ogies) supplemented with 10% heat-inactivated FCS, 50
µg/ml streptomycin, and 50 µg/ml penicillin at 37°C, 5%
CO2 and could be maintained in culture for 10–12 days.
Adenoviral transduction of lymphoma cells
Transduction of lymphoma cells with CsCl-purified aden-
ovirus was carried out in 24-well plates with 5 × 105 cells
in 50 µl of PBS plus 1 mM MgCl2/1% HS, at different mul-
tiplicities of infection (MOI). After 2 hours of incubation
at 37°C, 5% CO2, 1 ml of complete culture medium was
added to the cells. Because no visible toxic effect was
observed in comparison with the controls (only PBS plus
1 mM MgCl2/1% HS), it was not necessary to remove the
virus. Adenoviral transduction of primary lymphoma cells
was considered successful if concurrent CD19 expression
with green fluorescent protein (GFP) was observed.
Adenoviral vector preparation
The recombinant adenoviral Ad.GFP vector (pQB-
AdBM5GFP), an E1- and E3-deleted replication-defective
adenovirus type 5 under control of the cytomegalovirus
(CMV) promoter, was purchased from Quantum Biotech-
nologies (Montreal, Canada). The adenovirus vector
(Ad.IL-2) containing the human IL-2 sequence was kindly
provided by Frank L. Graham, McMaster University, Ham-
ilton, Ontario, Canada [10]. The E1/E3-deleted recom-
binant Ad5 vector expresses human IL-2 under control of
the CMV immediate early promoter (HCMV IE) and the
simian virus 40poly(A) signals (SV40 An). The Ad.Flexi-
12 vector contains cDNA that encodes a single-chain pro-
tein, called Flexi-12, which retains all of the biological
characteristics of recombinant IL-12 [11]. This E1/E3-
deleted recombinant adenovirus type 5 was generated
using the AdEasy system [12] and was kindly provided by
Robert Anderson, Royal Free Hospital School of Medicine,
London, UK. Infection of Ad.Flexi-12 can be tracked using
GFP expression analysis which is present as an additional
expression cassette in the viral genome.
Production of the adenovirus lots was performed as
described previously [7]. Briefly, near confluent 911 cell
monolayers in 175-cm2 flasks were infected with ~5
plaque-forming units (PFU)/cell in 2 ml of phosphate-
buffered saline (PBS) containing 1% horse sera (HS).
After 2 hours incubation at 37° in a humidified atmos-
phere of 5% CO2, the inoculum was replaced by fresh
medium (DMEM/2% HS). After 48 h, nearly completely
detached 911 cells were harvested and collected in 1 ml
PBS/1% HS. Virus was isolated by three cycles of flash-
freeze thawing. The lysates were cleared by centrifugation
at 3000 rpm for 10 minutes. Viruses were then purified on
double cesium chloride gradients and stored in PBS/10%
glycerol at -80°C.
Plaque assays were essentially performed as described by
Graham and Prevec [13]. Briefly, adenovirus stocks were
serially diluted in 2 ml of DMEM (Life Technologies) con-
taining 2% HS and added to nearly confluent 911 cells in
6-well plates. After 2 hours of incubation at 37°C, 5%
CO2, the medium was replaced by F-15 minimal essential
medium (Life Technologies) containing 1% agarose
(Sigma, Deisenhofen, Germany), 20 mM N-2-hydrox-
yethylpiperazine-N'-2-ethanesulfonic acid (pH 7.4),
0.0025% L-Glutamine, 5% yeast extract, 8.4% NaHCO3,
50 µg/mL streptomycin, 50 µg/mL penicillin, and 2% HS.
The titers of the virus stocks were at least 1 × 1010 PFU/ml.
IL-2 and IL-12 enzyme-linked immunosorbent assays 
(ELISA)
IL-2 and IL-12 levels in conditioned medium were deter-
mined by an enzyme-linked immunosorbent assay
(ELISA) method. The ELISA reagents were purchased from
Endogen, (Cambridge, USA). Briefly, a microtiter plate
was coated with a monoclonal antibody specific for IL-2
or IL-12. The IL-12 antibody recognizes only the p70 het-
erodimer and neither of the individual subunits, p35 or
p40, or the homodimeric form of p40. The cytokines
present in samples are bound by the immobilized anti-
body. After several washes to remove unbound proteins,
an enzyme-linked (horseradish peroxidase) polyclonal
antibody was added to the wells which binds IL-2 or IL-
12. After washing, the substrate solution was added, and
the color which developed was measured using a spectro-
photometer at a wavelength of 450 nm. The optical den-
sity of the samples was then compared to a standard
curve.
Cell proliferation assays
An MTT (3-(4,5-dimethylthiazol-2yl)-2,5-diphenyl tetra-
zolium bromide) based colorimetic assay [14] was per-
formed to measure the proliferative activity of PBMC
stimulated with cytokines either derived from superna-
tants of transduced Raji cells or recombinant with or with-
out addition of neutralizing anti-IL-2 or anti-IL-12
antibodies. In brief, 2 × 105 PBMC were incubated in 96-
well flat-bottom plates (Nunc, Denmark) in a final vol-
ume of 200 µl per well. After 3 days 20 µl of EZ4U reagent
(Biozol, Eching, Germany) was added to each well and
results were obtained on a multi-well scanning spectro-
photometer at 450 nm.
Cytotoxicity assays
A EuTDA nonradioactive cytotoxicity assay (Wallac,
Turku, Finland) was used to compare the cytotoxic activity
of IL-2 and IL-12 stimulated PBMC against unmodified
lymphoma cells [15]. This assay is a colorimetric alterna-
tive to the 51Cr release assay. The procedure is based on
loading the target cells with a fluorescence enhancing lig-
and (BATDA, bis(acteoxymethyl)2,2:6,2-terpyridine-6,6-Page 3 of 8
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membrane quickly and within the cell the esterbonds are
hydrolysed to form a hydrophilic ligand (TDA, 2,2:6,2-
terpyridine-6,6-dicarboxylic acid) which no longer passes
the membrane. After cytolysis the ligand is released and
introduced to the europium solution. The europium and
the ligand form a highly fluorescent and stable chelate
(EuTDA). The measured signal correlates directly with the
amount of lysed cells.
Briefly, 2 × 106 lymphoma cells were washed and resus-
pended in 2 ml PBS. 4.5 µl BATDA solution was added
and incubated at 37° for 30 min. Then, cells were washed
3 times, resuspended in 100 µl PBS, and incubated in 96-
well flat-bottom plates (Nunc) at a density of 10,000
cells/well. 100 µl of effector PBL cells of varying cell con-
centations were added so that effector to target cell ratio
ranged from 5:1 to 20:1. After incubation at 37° for 2 h
cells were centrifuged for 5 min at 500 × g and 20 µl of the
supernatant was transfered to a new flat-bottom plate.
180 µl of Europium solution was added, and after 15 min
incubtion at room temperature the fluorescence was
measured in a time-resolved fluorometer (Wallac). The
percent specific release was calculated from
Statistical analysis
Wilcoxon matched-pairs test was used to analyze for sta-
tistical significance. A p value < 0.05 was considered sig-
nificant. Data is presented as the mean ± standard error of
the mean (SEM).
Results
Transduction efficiencies of lymphoma cells and CAR/
integrin expression
Lymphoma cell lines, primary lymphoma cells, and CIK
cells were transduced with Ad.Flexi-12 at various MOI (0,
50, 100, 200) and analyzed 72 h later. Transduction effi-
ciencies were determined by GFP expression analysis using
a fluorescence-activated cell sorter (FACS). Additionally,
cell surface antigens were analyzed by FACS for the expres-
sion of CD19, integrin avβ3, integrin avβ5, and CAR. Ade-
noviral transduction of primary lymphoma cells was
considered successful if concurrent CD19 expression with
GFP was observed. It was demonstrated that most B cell
lymphoma cell lines could be transduced with much higher
efficiency than primary tumor samples or CIK cells. At an
MOI of 200, up to 40% of Daudi cells and 70% of Raji cells
could be transduced (Fig. 1A). In contrast, primary B-CLL
cells were found to be relatively resistant with transduction
efficiencies up to 6 %, whereas OCI-Ly8-Lam53 (LAM53)
cells, primary IC cells, and CIK cells were completely refrac-
tory (Fig. 1B). Transduction efficiency could be correlated
with the expression of CAR. High expression of CAR was
evident in Raji and Daudi cells, averaging 72% and 86%,
respectively. Primary B-CLL cells were found to have mod-
erate CAR expression of 36%. In contrast, there was no CAR
expression detectable in LAM53, IC, and CIK cells (Table
1). Expression of integrin receptors, however, was low or
absent in all lymphoma cells examined.







Transduction efficiencies in various human lymphoma cell lines (A), primary human lymphoma cells, and CIK cells (B)Figure 1
Transduction efficiencies in various human lymphoma cell lines (A), primary human lymphoma cells, and CIK cells (B). All cell 
types were transduced with Ad.Flexi-12 at various MOI as indicated and analyzed for GFP expression 72 h later by FACS anal-
ysis (mean ± SEM; n = 3).Page 4 of 8
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Cytokine gene expression was analyzed in lymphoma cell
lines using an ELISA assay as described above. Daudi, Raji,
and LAM53 cells were infected with Ad.IL-2 or Ad.Flexi-12
at various MOI (0, 50, 100, 200) with Ad.GFP as a control
vector. Cytokine production was assayed 72 h post-infec-
tion. As shown in Fig. 2A, IL-2 produced by Ad.IL-2-trans-
duced Raji and Daudi cells at an MOI of 200 averaged
10.6 ng/ml/106 cells and 2.7 ng/ml/106 cells, respectively.
In contrast, there was no IL-2 detectable in Ad.IL-2-trans-
duced LAM53 cells. Kinetic analysis of IL-2 production in
Raji cells revealed peak secretions between day 2 and 3. IL-
2 was detectable until day 8 post-infection (Fig 2B). Simi-
larly, IL-12 gene expression of Ad.Flexi-12 transduced Raji
and Daudi cells revealed 219 ng/ml/106 cells and 15.6 ng/
ml/106 cells, respectively. No expression was detectable in
Ad.Flexi-12-transduced LAM53 cells (Fig. 3A). Peak
expression of IL-12 was evident between day 1 and 3, with
IL-12 detectable by ELISA until day 10 post-infection (Fig.
3B).
Increase in proliferation rates of PBMC stimulated with 
adenoviral-expressed cytokines
To determine if adenoviral-expressed cytokines from
transduced lymphoma cells would have an impact on the
proliferation rates of PBMC from healthy donors, the fol-
lowing experiment was performed. PBMC were freshly
isolated and various concentrations of cytokines (1–1000
pg/ml) either derived from the supernatants of transduced
lymphoma cells or recombinant were added. Then, an
MTT assay to assess the proliferation rate was performed
five days later. For blocking experiments, a neutralizing
monoclonal antibody against IL-2 or IL-12 was used. Fig-
ure 4 shows that addition of adenoviral-expressed IL-2
(Fig. 4A) and IL-12 (Fig. 4B) led to dose-dependent
increases in proliferation rates of PBMC. There was no sig-
nificant difference between the effects of both cytokines.
Furthermore, the proliferative effect could be blocked by
Table 1: Expression analysis of adenovirus binding (CAR) and internalization receptors (avβ3, avβ5) on various human lymphoma cell 




Raji 72.5 ± 6.2 1.2 ± 0.1 1.0
Daudi 86.3 ± 1.8 1.1 ± 0.1 1.0
OCI-Ly8-LAM53 3.9 ± 1.5 1.1 ± 0.1 1.0
Primary cells:
B-CLL 36 ± 6.4 0.6 13.6
IC 3.2 n.d. n.d.
CIK 1.3 ± 0.2 15.0 2.0
IL-2 gene expression analysis in human lymphoma cell lines by using an ELISA ass yFigur  2
IL-2 gene expression analysis in human lymphoma cell lines 
by using an ELISA assay. (A) Daudi, Raji and LAM53 cells 
were infected with Ad.IL-2 or Ad.GFP at various MOI (0, 5, 
100, 200). 72 h post-infection, IL-2 produced by Ad.IL-2-
transduced Raji and Daudi cells at an MOI of 200 averaged 
10.6 ng/ml/106 cells and 2.7 ng/ml/106 cells, respectively 
(mean ± SEM; n = 3). (B) Kinetic analysis of IL-2 production 
in Raji cells transduced at an MOI of 200 revealed peak 
secretions between day 2 and 3 and IL-2 was detectable until 
day 8 post-infection (mean ± SEM; n = 3). All experiments 
were performed in triplicates.Page 5 of 8
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cytokine. Finally, it was demonstrated that there was no
significant difference between adenoviral-expressed and
recombinant cytokines.
Cytolytic activity of co-cultured PBMC against unmodified 
lymphoma cells
Raji cells were transduced with Ad.IL-2 (MOI 200),
Ad.Flexi-12 (MOI 200), or Ad.IL-2 and Ad.Flexi-12
together (MOI 100 each) and co-cultured with PBMC for
72 h. Non-transduced (control) and Ad.GFP transduced
Raji cells were used as controls. Stimulated PBMC were
harvested and assayed for their cytolytic activity against
unmodified lymphoma cells using a EuTDA nonradioac-
tive cytotoxicity assay. It could be shown that Ad.IL-2
transduced lymphoma cells produced a significant (p <
0.05) anti-tumor effect but not the combined effect of
Ad.IL-2/Flexi-12 or Flexi-12 alone (Fig. 5).
Discussion
The rationale for genetically modified lymphoma cell vac-
cines is to augment the immunogenicity of poorly immu-
nogenic lymphoma cells, thereby eliciting a systemic
immune reponse that is capable of controlling the dissem-
inated disease. Transgene candidates to potentially
achieve that goal include genes encoding for cytokines,
lymphotactic chemokines, allogeneic MHC molecules, or
co-stimulatory molecules [4]. The co-stimulatory mole-
cule CD40 ligand expressed from a recombinant adenovi-
ral vector in autologous chronic lymphocytic leukemia
cells has been tested in a recent clinical trial with encour-
aging results. [16]. Immunotherapy that combines two or
more of these immunostimulatory molecules will likely
(A) IL-12 gene expression of Ad.Flexi-12 transduced Raji and Daudi cells rev aled 219 ng/ml/106 cells and 15.6 ng/ml/106 cells at 72 h post-infectio , respective y (mean ± SEM; n = 3)Figure 3
(A) IL-12 gene expression of Ad.Flexi-12 transduced Raji and 
Daudi cells revealed 219 ng/ml/106 cells and 15.6 ng/ml/106 
cells at 72 h post-infection, respectively (mean ± SEM; n = 3). 
No expression was detectable in Ad-Flexi-12 transduced 
LAM53 cells. (B) Peak expression of IL-12 in transduced Raji 
cells was evident between day 1 and 3, with IL-12 detectable 
until day 10 post-infection (mean ± SEM; n = 3). All experi-
ments were performed in triplicates.
PBMC were incubated with cytokines (1–1000 pg/ml) either derived from supernatants of transduced Raji cells or recom-binant ith supernat nts fr m Ad.GFP-transduced Raji cells as controls and ass yed fo  their prolif rative a tivity (m an± SEM; n = 3)Figure 4
PBMC were incubated with cytokines (1–1000 pg/ml) either 
derived from supernatants of transduced Raji cells or recom-
binant with supernatants from Ad.GFP-transduced Raji cells 
as controls and assayed for their proliferative activity (mean 
± SEM; n = 3). Adenoviral-expressed IL-2 (A) and IL-12 (B) 
led to dose-dependent increases in proliferation rates of 
PBMC. No significant difference between the effects of either 
cytokine was found. The proliferation effect could be blocked 
by addition of a neutralizing antibody against either cytokine. 
There was no significant difference between the effects of 
adenoviral-expressed or recombinant cytokines. MTT assays 
were performed in triplicates.Page 6 of 8
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regard, adenoviral-mediated expression of both the IL-2
and IL-12 cytokine genes in several solid tumor models
has been found to induce strong and specific anti-tumor
responses [5,18]. Interestingly, Wang et al. demonstrated
that IL-2 enhances the reponse of NK cells to IL-12
through up-regulation of the IL-12 receptor, signal trans-
ducer, and transcription protein STAT4 [19]. Therefore,
we were interested in evaluating the potential of IL-2 and
IL-12 transduced lymphoma cells for their ability to stim-
ulate and activate immunologic effector cells.
Lymphoma cells are relatively resistant to transduction
with most currently available vector systems [20,21]. This
problem may be overcome ex vivo by using Epstein-Barr
virus vectors [22], adeno-associated virus vectors [23], or
modified adenoviral vectors [24,25]. Recently, we
described a transduction method accomplishing highly
efficient adenoviral-mediated gene transfer in lymphoma
cells [6]. Using this protocol, expression of the wild-type
p53 tumor-suppressing gene in lymphoma cell lines with
mutant p53 showed increased sensitivity to cytotoxic drug
and immuno-mediated toxicity [26]. In the current study,
we observed low expression levels of cell surface integrins
avβ3 and avβ5 on all lymphoma cells studied, which sug-
gests that the adenoviral entry into these cells may be
mediated by CAR, expressed at high levels on Raji and
Daudi cells. As a consequence, Raji and Daudi lymphoma
cell lines could be transduced with higher efficiency,
whereas primary lymphoma cells and normal
lymphocytes with low-level expression of CAR were
refractory. Turturro et al. have also shown that anaplastic
large cell lymphoma cells express high levels of CAR and
integrins, which could be transduced by adenoviral vec-
tors with high efficiency [27]. These results indicate the
importance of determining the expression levels of CAR
and integrins in tissues or cells derived from patients for
the generation of adenoviral vector-modified lymhoma
cell vaccines. Previously reported transduction efficiencies
of adenoviral vector-transduced lymphoma cells were
obtained with non-purified viruses [6]. Since this protocol
is not feasible for clinical application, the present studies
were performed with CsCl-purified viruses and lower
transduction efficiencies were achieved. The exact reason
for this difference is currently unknown and will be eluci-
dated in the future.
In our hands, human Burkitt's lymphoma cell lines were
most efficiently transduced with adenoviral vectors.
Expression of IL-2 and IL-12 cytokines in Raji cells trans-
duced at a relatively low MOI of 200 was transient, peaked
between 1 and 3 days post-infection, and was detectable
up to 10 days. The produced cytokines were assayed for
their biological ability to stimulate PBMC from healthy
donors in comparison with recombinant cytokines as
controls. Our data indicates that adenoviral expressed
cytokines were equally effective compared with recom-
binant cytokines in enhancing the proliferation rates of
PBMC. This effect could be blocked by the addition of
neutralizing antibodies against either cytokine. In a cyto-
toxicity assay, IL-2 stimulated PBMC were able to lyse
unmodified Raji cells, while IL-12 or the combined IL-2
and IL-12 stimulated PBMC were clearly less effective.
Previously, we have shown that cytotoxic CD8+ NKT cells
are readily expandable in vitro in large quantities suitable
for adoptive immunotherapy. These activated effector
cells have significant cytotoxic activity against human
lymphoma xenografts with limited toxicity [8,28]. We
have also demonstrated that CD8+ NKT cells can be gen-
erated in vitro using either IL-2 or IL-12 [29]. Interest-
ingly, adoptive T cell therapy combined with intratumoral
administration of adenoviral expressed IL-12 was shown
to have strong synergistic effects against large transplanted
tumors [30]. Therefore, expression of IL-2 and IL-12 in
lymphoma cells may be used to further increase their sen-
sitivity towards adoptively transferred CD8+ NKT cells in
the future.
Conclusion
This study demonstrates that the generation of recom-
binant adenovirus modified lymphoma cell vaccines
based on lymphoma cell lines expressing IL-2 and IL-12
cytokine genes is technically feasible, induces increases in
Raji cells were transduced with Ad.Flexi-12 (MOI 200), or Ad.IL-2 and Ad.Flexi-12 (MOI 100 each) and co-cultured with PBMC for 72 hFigure 5
Raji cells were transduced with Ad.IL-2 (MOI 200), Ad.Flexi-
12 (MOI 200), or Ad.IL-2 and Ad.Flexi-12 (MOI 100 each) 
and co-cultured with PBMC for 72 h. Non-transduced (con-
trol) and Ad.GFP-transduced Raji cells were used as controls. 
Stimulated PBMC were harvested and assayed for their cyto-
lytic activity against unmodified lymphoma cells by using an 
EuTDA non-radioactive cytotoxicity assay. Ad.IL-2-trans-
duced lymphoma cells elicited a significant anti-tumor effect 
but not the combined effect of IL-2/IL-12 or IL-12 alone 
(mean ± SEM; n = 5; * p < 0.05).Page 7 of 8
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PBMC, and warrants further development for the treat-
ment of lymphoma patients in the future.
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